Management of bone metastases in refractory prostate cancer – role of denosumab
Channing J Paller,1 Michael A Carducci,1 George K Philips21Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; 2Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USAAbstract: This article reviews the problem of bone disease in prostate cancer and the evolvin...
Guardado en:
Autores principales: | Paller CJ, Carducci MA, Philips GK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3ae174c8e253409dbf5d3154d0a4d053 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
por: Yee AJ, et al.
Publicado: (2012) -
Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas KM, et al.
Publicado: (2014) -
High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
por: Ishikawa K, et al.
Publicado: (2018) -
Clinical utility of denosumab for treatment of bone loss in men and women
por: Adler R, et al.
Publicado: (2011) -
Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Piet Geusens
Publicado: (2009)